



Investor Presentation July 2021



Disclaimer



Disclaimer

This presentation is for information purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between HeartFlow Holding, Inc. (“HeartFlow”) and Longview Acquisition Corp. II (“Longview”). The information contained herein does not purport to be all-inclusive, and none of HeartFlow, Longview, or any of their prospective affiliates, or any of their control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this presentation, you confirm that you are not relying upon the information contained herein to make any decision.

Forward-Looking Statements

This document includes certain statements, estimates, targets, forward-looking statements and projections (collectively, “forward-looking statements”) that reflect assumptions made by HeartFlow concerning anticipated future performance of HeartFlow and its industry. Such forward-looking statements are based on significant assumptions and subjective judgments concerning anticipated results, which are inherently subject to risks, variability and contingencies, many of which are beyond HeartFlow’s control. Factors that could cause actual results to differ from these forward-looking statements include, but are not limited to, HeartFlow’s limited commercial track record, levels of adoption of the HeartFlow Analysis by healthcare providers, the availability and adequacy of coverage and reimbursement for the HeartFlow Analysis, HeartFlow’s ability to obtain regulatory approvals and comply with legal and regulatory requirements, healthcare industry trends, competition, general economic conditions and the availability and terms of financing. Such forward-looking statements may be identified by the use of words like “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “will”, “should”, “seek”, “can”, “continue”, “shall”, “would”, “predict”, “potential”, “seem”, “future”, “outlook” and similar expressions and include any financial projections or estimates or pro forma financial information set forth herein. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Neither Longview nor HeartFlow undertake any duty to update these forward-looking statements or the other information contained in this presentation. Neither Longview nor HeartFlow makes any representation or warranty, express or implied, as to the accuracy or completeness of this document or any other information (whether written or oral) that has been or will be provided to you. Nothing contained herein or in any other oral or written information provided to you is, nor shall be relied upon as, a promise or representation of any kind by Longview or HeartFlow. Without limitation of the foregoing, Longview and HeartFlow expressly disclaim any representation regarding any projections concerning future operating results or any other forward-looking statement contained herein or that otherwise has been or will be provided to you. Neither Longview nor HeartFlow shall be liable to you or any prospective investor or any other person for any information contained herein or that otherwise has been or will be provided to you, or any action heretofore or hereafter taken or omitted to be taken, in connection with this potential transaction.

Use of Projections

This Presentation contains financial forecasts with respect to HeartFlow’s projected financial results for its fiscal years 2021 through 2025. HeartFlow’s independent auditors have not audited, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this Presentation, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto for the purpose of this Presentation. These projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Accordingly, there can be no assurance that the prospective results are indicative of the future performance of HeartFlow, or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this Presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved.

Disclaimer (continued)



Industry and Market Data

In this Presentation, Longview and HeartFlow rely on and refer to certain information and statistics obtained from third-party sources which they believe to be reliable. Neither Longview nor HeartFlow has independently verified the accuracy or completeness of any such third-party information.

Trademarks

This Presentation contains trademarks, service marks, trade names and copyrights of Longview, HeartFlow and other companies, which are the property of their respective owners.

Important Information About the Business Combination and Where to Find It

In connection with the proposed Business Combination, Longview intends to file with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 (the "Registration Statement"), which will include a preliminary proxy statement/prospectus and a definitive proxy statement/prospectus, and certain other related documents, which will be both the proxy statement to be distributed to holders of shares of Longview's common stock in connection with Longview's solicitation of proxies for the vote by Longview's stockholders with respect to the Business Combination and other matters as may be described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities of Longview to be issued in the Business Combination. Longview's stockholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus included in the Registration Statement and the amendments thereto and the definitive proxy statement/prospectus, as well as other documents filed with the SEC in connection with the proposed Business Combination, as these materials will contain important information about the parties to the Business Combination Agreement, Longview and the proposed Business Combination. After the Registration Statement is declared effective, the definitive proxy statement/prospectus and other relevant materials for the proposed Business Combination will be mailed to stockholders of Longview as of a record date to be established for voting on the proposed Business Combination and other matters as may be described in the Registration Statement. Stockholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC's web site at www.sec.gov, or by directing a request to: Longview Acquisition Corp. II, 767 Fifth Avenue, 44th Floor, New York, NY 10153, Attention: Mark Horowitz, Chief Financial Officer or to info@longviewacquisition.com.

Participants in the Solicitation

Longview and its directors and executive officers may be deemed participants in the solicitation of proxies from Longview's stockholders with respect to the Business Combination. A list of the names of those directors and executive officers and a description of their interests in Longview will be contained in the Registration Statement for the Business Combination, when available, and will be available free of charge at the SEC's web site at www.sec.gov, or by directing a request to Longview Acquisition Corp. II, 767 Fifth Avenue, 44th Floor, New York, NY 10153, Attention: Mark Horowitz, Chief Financial Officer or to info@longviewacquisition.com. Additional information regarding the interests of such participants will be contained in the Registration Statement when available. HeartFlow and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Longview in connection with the Business Combination. A list of the names of such directors and executive officers and information regarding their interests in the Business Combination will be contained in the Registration Statement when available.

No Offer or Solicitation

This presentation shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This presentation shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Today's Presenters



Transaction Overview

Company Overview



Larry Robbins
Chairman
Longview Acquisition Corp. II



John Stevens, M.D.
President & CEO, Co-founder
HeartFlow



Charles A. Taylor, Ph.D.
Founder, Chief Technology Officer
HeartFlow



GLEACHER & COMPANY



Amp Resources

HEARTPORT



Transaction Overview

HeartFlow is preparing to go public through a SPAC Merger with Longview Acquisition Corp. II



- HeartFlow Holding, Inc. (“HeartFlow”) is revolutionizing precision “heart care” with non-invasive personalized cardiac tests and enterprise software suite solutions, which provide unprecedented assessment of patients’ coronary artery anatomy and function, enabling physicians to make more informed care decisions in order to drive better outcomes and lower costs
- Pre-SPAC funding of \$543 million helped to create a significant IP portfolio with 400+ issued patents worldwide built upon 25 years of innovation beginning at Stanford University



- Longview Acquisition Corp. II (“Longview II”) is a Special Purpose Acquisition Corporation (“SPAC”) brought public as an affiliate of Glenview Capital Management
- Initially capitalized with \$690 million in cash in trust in March 2021 trading under the ticker LGV
- Glenview Capital was founded in 2000 by Larry Robbins and is currently in its 21st year of active public markets investing with a focus on the healthcare market

HeartFlow and Longview II signed a Letter of Intent on June 14, 2021 and entered into a definitive merger agreement on July 15, 2021. The parties seek to close the merger in 4Q 2021.

Transaction Overview



Key Highlights

- HeartFlow will be appropriately capitalized with ~\$400mm of net cash (assuming no redemptions) post-closing
- Up to \$91mm of cash in trust will be returned to LGV shareholders via special dividend immediately prior to closing
- LGV shareholders will receive approximately \$1.319 per share (based off of 69mm shares outstanding) concurrent with closing and LGV will implement a reverse split of ~0.868:1 to re-establish a base investment price of \$10.00 per LGV share
- No PIPE was required given a) the size of the LGV SPAC and b) the high caliber of pre-existing shareholders rolling equity including Baillie Gifford, Blue Venture Fund, HealthCor, and Wellington, among others
- In an expression of partnership and long-term optimism in the growth investment case, Longview committed to a 3-year lock-up on its sponsor shares
- In the interest of alignment and capital efficiency, LGV will surrender sponsor shares on a pro-rata basis to the pre-closing return of excess capital
- Vast majority of prior shareholders rolling equity with de minimis (~5%) secondary purchases for early venture investors and employees with greater than 8 years tenure
- The parties seek to close the merger in 4Q 2021

(\$ in mm, except per share values)

Sources

Equity to HeartFlow Stockholders	\$2,150.0
Longview Cash Held in Trust ¹	690.0
Pre-Closing Return of Capital ^{1,2}	(91.0)
Total Sources²	\$2,749.0


Uses

Equity to HeartFlow Stockholders	\$2,150.0
Cash to Balance Sheet ^{1,2}	346.5
Cash for Secondary Purchases	110.0
Debt Retirement, Interest and Related Fees ⁴	74.2
Transaction Fees and Expenses	46.2
Deferred Underwriting Fee	22.2
Total Uses	\$2,749.0

Pro Forma Valuation

Share Price	\$10.00
Diluted Shares Outstanding ³	277.375
Equity Value	\$2,773.8
(+) Debt ⁴	--
(-) Cash ⁵	400.0
Enterprise Value	\$2,373.8
	<u>2023E</u> <u>2024E</u> <u>2025E</u>
Revenue	\$205 \$345 \$525
EV / Revenue	11.6x 6.9x 4.5x

Illustrative Pro Forma Ownership



1. Assumes no redemptions.

2. Excludes the Forward Purchase Agreement (FPA) provided by funds managed by Glenview Capital Management, LLC. The FPA provides a backstop for the first \$25mm of redemptions of Longview common stock at \$10 per share. Additionally, if redemptions exceed \$200mm, the FPA provides for a backstop of up to another \$25mm of redemptions of Longview common stock at \$10 per share.

3. Estimated fully diluted shares outstanding based on (i) 250.0mm common shares owned by: Longview Public Shareholders (59.9mm); Longview Sponsor/Board (15.0mm); and legacy HeartFlow (175.1mm); (ii) 37.4mm warrants and options outstanding held by legacy HeartFlow to be exercised using the Treasury Stock Method (27.4mm net); and (iii) excluding 12.0mm Longview public warrants and 8.5mm Longview sponsor warrants.

4. Projected HeartFlow debt at 06/30/21; assumes \$74.2mm of debt retired with transaction proceeds.

5. Projected HeartFlow cash balance at 06/30/21 of \$82mm less projected cash burn through transaction closing of \$29mm plus cash to balance sheet of \$346mm.

HeartFlow Met Every Longview Criteria



Address a Significant, Unmet Medical Need

- Heart disease is #1 cause of death
- Largest component of chronic health spend
- Current imaging standard of care is fundamentally flawed



Proprietary, Innovative Technology With Significant Intellectual Property Portfolio

- 400+ issued patents worldwide
- Highest cardio diagnostic accuracy driven by big data analytics



More for Less – Clinical Benefit and Systemic Cost Reduction Broadly Cited

- 425+ peer-reviewed publications, included in clinical practice guidelines
- FDA clearance, CE Mark, Japan PMDA Approval
- US coding, coverage and payment established, Medicare + 96% of commercial payers



Highly Attractive Business Model

- SaaS model combining fee-per-analysis and subscription
- Developing integrated, cloud-based heart care tech product suite



Compelling Investment Driven By a Significant Growth Opportunity and Reasonable Valuation

- Opportunity within \$50B TAM to move from a “fraction of a fraction” of testing today to a “majority of a majority” with a more robust standard of care
- Brought public at 11.6x EV / 2023E Revenue for premier precision healthcare growth asset


Executive Summary



- 1 Driven by a mission to **improve cardiovascular care for patients, physicians, providers and payers...**
- 2 Addressing the **number one cause of death** and largest component of chronic health spend...
- 3 HeartFlow developed and introduced a **revolutionary precision “heart care” technology that disrupts the status quo...**
- 4 Empowering physicians with an **AI-enabled, cloud-based enterprise software suite...**
- 5 Transforming cardiovascular disease **risk assessment, diagnosis, planning, and treatment management...**
- 6 Delivering **precise, personalized and enhanced care decisions** for patients...
- 7 Providing **significant clinical evidence**, leveraging a **strong intellectual property portfolio...**
- 8 **Unlocked barriers driving adoption** by key cardiology societies, providers and payers...
- 9 **Aligned with and enabling of healthcare’s mega trends...**
- 10 With a **predictable and attractive SaaS model** combining fee-per-analysis and base subscription layers...
- 11 Augmented by a **robust software pipeline** to fuel a **significant TAM** story for years to come...
- 12 Fueling a **compelling high growth outlook...**
- 13 Brought to the market at an **attractive valuation...**
- 14 Led by a **strong team...**
- 15 Fortified by **experienced investment partners...**
- 16 Collectively driving **societal and commercial impact by enabling access to optimized care for all patient populations.**

1

Driven by a Mission to Improve Cardiovascular Care for Patients, Physicians, Providers and Payers





2 Addressing the Number One Cause of Death and Largest Component of Chronic Health Spend

1 out of every 3
deaths

More than twice as many
deaths as the 2nd most
common cause (cancer)

1 billion people in the world at
moderate to high risk today



American
Heart
Association
Center for Health Metrics and Evaluation

Cardiovascular Disease Costs Will Exceed \$1 Trillion by 2035, Warns the American Heart Association

Nearly Half of Americans Will Develop Pre-existing CVD Conditions

About **1 in every 6 health care dollars** is spent on cardiovascular disease...



The “Status Quo” Heart Disease Care Pathway Dominated by Echo & Nuclear Stress Testing is Suboptimal

3

Risk Assessment



Multiple possible starting points

Annual Physical

Blood Pressure

Blood Tests

Body Mass Index

Calcium Scoring


Non-invasive Testing

10M non-invasive tests in the US alone every year



Multiple layers of testing


Stress Echocardiography



Treadmill ECG



SPECT & PET Nuclear Scans



Invasive Testing

2M+ catheterizations in the US alone every year³

UNNECESSARY PROCEDURES

55% FALSE POSITIVES: Patients sent for an invasive angiogram have **no obstructive coronary artery disease (CAD)**¹

UNDETECTED DISEASE

20-30% FALSE NEGATIVES: Patients sent home with their **undetected coronary disease**²



Reliance on Invasive Pathway for Confirmation

1. Patel, et al. N Engl J Med 2010. Patel, et al. AHJ 2014. Danad, et al. JAMA Cardiology 2017.
 2. Arbab-Zadeh, Heart Int 2012. Yokota, et al. Neth Heart J 2018. Nakanishi, et al. J Nucl Cardiol 2018.
 3. Maroney, et al. Catheterization & Cardiovascular Interventions 2012.



HeartFlow Developed and Introduced a Revolutionary Precision “Heart Care” Technology that Disrupts the Status Quo

HeartFlow’s product suite leverages and builds upon a foundational technology platform

Precision Diagnostics

Optimization of Therapy



Coronary Computed Tomography Angiography (CTA)







Informed Clinical Decision

Anatomic Stenosis¹

CTA-based Fractional Flow Reserve (FFR_{CT}) & Myocardial Blood Flow²

Plaque¹

Treatment Planning



Diagnosis

Treatment Optimization

Risk and Prognosis

1. Currently in development and not available for clinical use.

2. Images not representative of actual product.

Empowering Physicians with an AI-enabled, Cloud-based Enterprise Software Suite



HeartFlow[®]
FFR_{CT} Analysis




IMAGE IS NOT REPRESENTATIVE OF ACTUAL PRODUCT

ADVANCED TECH


- AI-powered modeling of all coronary arteries
- Highest diagnostic accuracy driven by big data analytics
- Compliant cloud computing to protect sensitive data
- Secure bi-directional data transmission to / from hospital IT systems

PATIENT-CENTRIC

- Helps explain symptoms, providing peace-of-mind
- Fewer physician visits, fewer tests, no additional radiation
- Non-invasive, virtual, integrates with telemedicine
- Easy to understand, personalized model available on any device (web, mobile, tablet, electronic health records)



5 Transforming Cardiovascular Disease Risk Assessment, Diagnosis, Planning, and Treatment Management



*Currently in development and not available for clinical use.



Monitor


- Ongoing patient monitoring coupled with patient history ensures physicians and patients will remain vigilant about CAD

Treat

- HeartFlow use leads to more informed and more personalized clinical care decisions which drives improved patient outcomes

Plan

- Physicians can use HeartFlow's Planner to virtually model clinical scenarios vessel-by-vessel, explore treatment strategies for patients with CAD before each procedure, review cases with colleagues, and ensure a clear picture of the initial treatment plan
- Reduces radiation exposure by up to 50% compared to a SPECT test




Assess

- The historical path to diagnosing CAD is unclear, unreliable, insufficient and ineffective
- Patients and staff benefit from a "one stop, closed loop test" that encourages dialogue between specialties

Diagnose

- The CTA + HeartFlow pathway enables physicians to more accurately diagnose patients with suspected CAD by combining two powerful, non-invasive technologies; coronary CTA and the HeartFlow Analysis
- Delivers superior per-vessel diagnostic performance than other non-invasive cardiac tests
- Provides anatomical and lesion-specific functional information in a single-patient visit
- Identifies functional disease other non-invasive cardiac tests may overlook



AGE: 60 SEX: MALE
HISTORY: SYMPTOMATIC, FAMILY HISTORY OF HEART DISEASE

*Currently in development and not available for clinical use.



7 Providing Significant Clinical Evidence

Since inception, HeartFlow has been committed to producing comprehensive clinical evidence to substantiate the diagnostic accuracy, safety, efficacy, cost-effectiveness, and utility of its product portfolio

ROBUST EVIDENCE

- » **16** company-sponsored **clinical trials and registries** addressing accuracy and outcomes
- » **100+** investigator-initiated studies
- » **425+** peer-reviewed publications, including *JAMA*, *JACC*, *Circulation*, *American Journal of Cardiology*, *European Heart Journal* and *Heart*
- » Studied in **>10,000 patients**
- » Demonstrated safety with **long-term data** out to **5 years**
- » Developed and trained on more than **15 million CT images**



Higher diagnostic accuracy than any other non-invasive cardiac test¹



83% reduction in unnecessary invasive coronary angiograms²



36% improvement in cath lab efficiency³



40% reduction in layered testing³



Better outcomes at lower costs than functional stress testing in cost-effectiveness analysis⁴



\$2.7B annual cost-savings delivered to CMS through reduction of invasive diagnostic procedures²

1. Driessen, et al. J Am Coll Cardiol 2019. Nørgaard, et al. J Am Cardiol 2014.

2. Douglas, et al. J Am Coll Cardiol 2016.

3. Curzen, et al. TCTConnect 2020.

4. Karády, et al. JAMA Network Open 2020.



7 Leveraging a Strong Intellectual Property Portfolio

HeartFlow's differentiated IP portfolio provides a powerful competitive advantage, while a significant imaging database fuels an AI-based technology roadmap to drive incremental automated product enhancements

400+

Issued
patents worldwide

Unmatched IP Portfolio Built on
25 Years of Innovation



15 Million+

Annotated CT Images

2 Petabytes+

of Coronary Imaging Data

Expected to double in next 12 months



8 Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers

HeartFlow has unlocked key barriers to adoption of their technology offering

Technology & Healthcare Competency	<ul style="list-style-type: none">✓ Experienced, diverse management team with relevant tech and cardiology backgrounds
Clinical Evidence	<ul style="list-style-type: none">✓ 425+ peer-review publications
Regulatory Clearance	<ul style="list-style-type: none">✓ FDA Clearance✓ CE Mark✓ Japan PMDA Approval
Business Model / Go-to-Market Strategy	<ul style="list-style-type: none">✓ Hybrid of fee-per-analysis and subscription
Society Endorsements	<ul style="list-style-type: none">✓ U.S.: Anticipated chest pain guidelines from American College of Cardiology (ACC) and AHA✓ Europe: Chronic coronary syndrome diagnosis guidelines from European Society of Cardiology (ESC)✓ Japan: Chronic coronary heart disease guidelines from Japanese Circulation Society (JCS)
Payer Coverage & Reimbursement	<ul style="list-style-type: none">✓ Coding: US CPT codes established + UK & Japan reimbursement coverage in-place✓ Coverage: US Medicare & 96% of US commercial lives✓ Prior Authorization: 69% of US covered lives have streamlined process

8 Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers



The CTA + HeartFlow pathway is recognized by key cardiology societies



Multimodality Cardiovascular Imaging in the Midst of COVID-19 Pandemic

"CTA can be used to rapidly evaluate multiple forms of cardiac disease" and "identifying patients with CAD who can be treated conservatively, (e.g., excluding high risk anatomy or through the use of FFR_{CT} to exclude functionally significant lesions)."

- ✓ HeartFlow is included in the ACC and AHA "appropriate use criteria" for coronary revascularization
- ✓ HeartFlow can be used in lieu of invasive alternatives in National Cardiology Data Registry to validate PCI appropriateness



2019 Guidelines on Diagnosis & Management of Chronic Coronary Symptoms (CCS)

*"Unless obstructive CAD can be excluded based on clinical evaluation alone, **either non-invasive functional imaging or anatomical imaging using coronary CTA** may be used as the initial test to rule out or establish the diagnosis of CCS."*



NICE

Clinical Guideline (CG95), Nov. 2016

- ✓ Prioritizes CTA pathway
- Medical Technologies Guidance (MTG32)**, Feb. 2017, Apr. 2021
- ✓ Endorses HeartFlow as essential part of CTA pathway

NHS

Innovation Technology Payment Programme, Apr. 2018

- ✓ Provides funding for full adoption across NHS Sites
- NHS England / NHS Improvement Funding Mandate**, Apr. 2021
- ✓ Mandates adoption of AI-powered HeartFlow to fight CHD



8 Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers

The CTA + HeartFlow pathway is trusted by leading US hospitals and has been prioritized by US payers



80% of the Top 50 Heart Hospitals¹ in the US Have Adopted HeartFlow

System-Wide Adoption

Large healthcare systems have initiated the adoption of the **CTA + HeartFlow pathway** for the majority of patients in need of a non-invasive test for CAD



Two Agreements Signed



Six Agreements Under Review

96%
US commercial lives covered

69%
Of US covered lives have streamlined prior authorization requirements

100%
Local coverage in the US with Medicare MACs²



1. Top 50 Heart Hospitals as designated by US News and World Report


2. Includes 71% coverage with local coverage determinations and 29% on a case-by-case basis



9

Aligned With and Enabling of Healthcare's Mega Trends

HeartFlow is the definition of value-based care



Value-Based Care

We believe the true way to deliver “better” healthcare while reducing costs is to equip clinicians with superior technology that fundamentally informs better care management decisions

Provider-Centric Approach

- Clinically superior, simple to-use, easy to interpret, with straightforward reimbursement
- Integrated with healthcare practitioner and powered by AI and deep ML to inform personalized medical

Improved Outcomes

- More precise diagnosis
- More informed risk assessment
- Optimized treatment strategies
- More proactive monitoring

Reduced Cost

- Optimal treatment for each patient
- Reduce unnecessary invasive coronary angiograms
- Reduce layered testing



Predictable and Attractive SaaS Model Combining Fee-per-analysis and Base Subscription Layers

Historically successful business model incorporates hybrid approach of fee-per-analysis (consumption based at a fixed per test rate) and enterprise software suite subscription (annual bundled contract)

Revenue Model



Fee-per-analysis

for delivery of **FFR_{CT}** and **Plaque¹**

Products

- *FFR_{CT}*
- *Plaque*



Subscription

provides access to bundle of **advanced product features**

Products

- *PreRead*
- *Myocardial Insights*
- *Planner*

Benefits


- Positions HeartFlow to be an indispensable partner for the development of CTA + HeartFlow diagnostic programs & treatment pathways
- Facilitates engagement of HeartFlow for all CTAs performed by a hospital / health system
- Facilitates appropriate penetration of FFR_{CT} based on CTA volume
- Enhances customer workflow and efficiency supporting growth and adoption of CTA

Comprehensive engagement with customer sites drives land, retain, and expand strategy

Augmented by a Robust Software Pipeline to Fuel a Significant TAM



HeartFlow is developing a comprehensive, integrated cloud-based heart care technology product suite to help physicians make more optimal cardiovascular care decisions



1. Anticipated regulatory approval following submission for regulatory clearance in 2H 2021. 2. Image not representative of actual product.




11 Augmented by a Robust Software Pipeline to Fuel a Significant TAM

From a fraction of a fraction to a majority of a majority

- Over the coming 15 years, we envision HeartFlow moving from a small minority of coronary CTA scans to being attached to the vast majority
- Additionally, over the same period we envision coronary CTA scans will move from 5% to 80% of patients based upon our current understanding of the safety and efficacy of HeartFlow FFR_{CT} compared with stress echo and nuclear SPECT stress testing alternatives

Non-Invasive Cardiac Testing Utilization as a Percentage of Cases


Today



In cases where CTA scans are used, HeartFlow FFR_{CT} is still under-penetrated

15 Years of Market Growth

Future



HeartFlow management believes that CTA + HeartFlow will become the dominant solution in cardiovascular disease management as a wholesale shift away from stress testing occurs

CTA + HeartFlow


CTA Only

Stress testing (echo and nuclear)



11 Augmented by a Robust Software Pipeline to Fuel a Significant TAM

HeartFlow has a clear projected development path to grow TAM from \$10B to \$50B+



1. Based on HeartFlow and Longview analysis. TAM shown is based on data for US, UK, Europe and Japan: Karády, et al. JAMA Network Open 2020; Wall, et al. Int J Cardiovasc Imaging 2011; Rahsepar, et al. Curr Cardiovasc Imaging Rep. 2015; Asher, et al. Openheart, 2019; Japan Circulation Society survey data, 2020; Wang et al. AJR Am J Roentgenol. 2008; Curzen, N. FORECAST Study, TCT 2020. 2019 Population US Census, Euro Stat, Office for National Statistics UK, Statistics Bureau of Japan; Yang et al. BMJ Open 2017; Hales CM, Carroll MD. NCHS Health E-Stat. 2020; 2013 ACC/AHA Guideline on the Assessment of cardiovascular risk; Choi et al. JACC 2008.




12 Fueling a Compelling High Growth Outlook


Management believes that HeartFlow's financial forecast is supported by a highly predictable and leverageable business model with a robust commercial pipeline, favorable industry tailwinds, and no customer churn

2021-2025 Plan

Revenue (\$ millions)



Gross Margin



Key Growth Drivers





















1. New customer site additions primarily in the US, the UK, and Japan
2. Increased utilization and attachment rate of FFR_{CT} to CTA at current sites
3. Launch of Enterprise Suite subscription inclusive of PreRead in 4Q22
4. Incremental guideline + reimbursement enhancements to place CTA on parity with SPECT
5. Cardiology suite shift from stress testing => CTA enhanced by HeartFlow
6. Execution of automation roadmap to drive case analysis / process efficiencies

*The financial information for 2020 is preliminary, unaudited and subject to revision upon completion of HeartFlow's closing and audit processes.



13 Brought to the Market at an Attractive Valuation

HeartFlow and Longview II believe HeartFlow is priced at a significant discount to the relevant comp sets despite offering materially faster revenue growth and superior margin prospects

	Revenue CAGR ^{1,2}		EV/Revenue ^{1,2}			% Gross Margin ^{1,2}	
	'21E-'23E	'21E-'25E	2023E	2024E	2025E	2023E	2025E
Disruptive Tools & Specialty Dx     	37%	21%	16.7x	13.4x	10.6x	75%	76%
High Growth MedTech      	42%	19%	11.7x	9.8x	8.2x	77%	79%
SaaS / Software        	23%	16%	18.0x	14.6x	12.0x	81%	82%
All Comparable Mean	33%	18%	15.7x	12.8x	10.4x	78%	80%
	120%	88%	11.6x	6.9x	4.5x	78%	85%

1. Bloomberg as of July 9, 2021. 2. Represents the mean for each trading comparable set unless otherwise noted.



Leadership Team



John Stevens, M.D.*
President & CEO, Co-founder
 Heartport, Amp Resources, Stanford University



William C. Weldon*
Board Chair
 Former Chairman & CEO, J&J



Charles A. Taylor, Ph.D.*
Founder, Chief Technology Officer
 Stanford University, GE



Campbell Rogers, M.D.
Chief Medical Officer
 Brigham & Women's Hospital, Johnson & Johnson



Nicky Espinosa
General Counsel, Chief Ethics and Compliance Officer
 Brobeck, Phleger & Harrison, Illumina, Intuitive Surgical



Lance Scott
Chief Commercial Officer
 Abbott, Zephyr Health, Edwards Lifesciences



Renata Naoumov
Chief People Officer
 Dow, GE, HSBC



Windi Hary
Chief Regulatory & Quality Officer
 Stentor, Philips



Christopher Zarins, M.D.
Founder, SVP, Medical Affairs
 Stanford University, Univ. of Chicago



Joost de Schutter
VP, Finance
 Thermo Fisher, Prysm, RenovoRX, Philips

Senior Team



Heather Brown
SVP, Market Access & Reimbursement
 3DR, Ziosoft



Tim Fonte
SVP, Customer Success
 Stanford University, Cameron Health



Dustin Michaels
SVP, Strategic Accounts
 FlowCardia, Percusurge, AneuRx



Auston Davis
VP, Chief Information Security Officer
 Stanford Children's Health, Visa, Symantec



Sophie Khem
VP, Process & Quality Engineering
 Boston Scientific, Evalve



Hisakazu Shimizu
GM, HeartFlow Japan
 Cardinal Health, Cordis



Christophe Lecas
VP, Engineering
 Microsoft, Samsung, Symantec



Sarah Mullen
VP, Clinical Operations
 Carbylan, Spiracur, ev3



Jennie Kim
VP, Global Marketing
 Abbott, MSL, Weber Shandwick



Souma Sengupta
VP, Upstream Marketing & CT Applications
 General Electric, Imatron



15 Fortified by Experienced Investment Partners



- Longview II is sponsored by an affiliate of Glenview Capital Management, a registered investment adviser
- Glenview brings extensive public market experience in the healthcare industry with a long-term orientation across provider, payer, distributor and medical product companies
- Culture of Suggestivism has created shareholder value and lasting bonds

Investment Professionals with Significant Knowledge and Experience

21st Year
Managing Funds

Meaningful LT
Outperformance vs.
S&P 500

13 Years
Average Tenure of
Senior Management

Extensive C-Level
Corporate Contacts

13
Company Stocks
Held for 10+ Years

300+
Industry Experts
Assist in the Creation of
Proprietary Research



Larry Robbins – Chairman, Longview Acquisition Corp. II

- CEO and Founder of Glenview Capital Management
- Board Chair: KIPP NY Inc.
- Lead Independent Director: Butterfly Network
- Board Member: Robin Hood Foundation, Zearn, Relay GSE
- Previously served as Partner at Omega Advisors and Associate at Gleacher & Co.



John Rodin – CEO, Longview Acquisition Corp. II

- Partner and Co-President of Glenview Capital Management for 17+ years
- Previously served as President of Fantex Brokerage
- Started his career with Goldman Sachs



Mark Horowitz – CFO, Longview Acquisition Corp. II

- Co-President of Glenview Capital Management for 17+ years
- Previously served on the senior management team at Axiom Legal Solutions
- Prior to that, worked as a corporate and securities lawyer at Cravath, Swaine & Moore and Brobeck, Phleger & Harrison



Lee Hathaway – Partner, Co-Head of Healthcare, Glenview Capital Management

- Partner and Co-Head of Healthcare of Glenview Capital Management for 9+ years
- Currently serves as a Director of Quanta Dialysis Technologies and Tesseract Health
- Prior healthcare investing experience in private equity at Water Street Healthcare Partners and investment banking within the Global Healthcare Group of Barclays Capital



Existing HeartFlow Investor Base



BLUE VENTURE FUND 

C▷PRICORN
INVESTMENTGROUP

 HealthCor

SBX

USVP
U.S. VENTURE PARTNERS

WELLINGTON
MANAGEMENT®

Enabling Access to Optimized Care for All Patient Populations



Investors' collective investment and partnership with HeartFlow will achieve meaningful societal goals

HeartFlow's Technical Strengths

**Disruptive, Best-in-class
Non-invasive
Precision Heart Care**

**Robust Intellectual
Property Estate**

**AI-powered Modeling with the
Highest Diagnostic Accuracy**

**Peer-review Publications, Medical
Society Endorsements, and Payer
Engagement**

**Attractive Hybrid
Commercial Model**

**Clinical, Regulatory,
Reimbursement and Commercial
Product Roadmap**

**Tailwind Due to Shift from Stress
Testing to CTA + FFR_{CT}**

**Expansion via Plaque and
Asymptomatic Assessment**

Societal & Commercial Opportunity

Improve Diagnostic Accuracy

Improve Quality of Care

Expand & Enhance Access to Care

Improve Patient Experience

Reduce Cost

Unlock & Penetrate Significant TAM



Thank You!

